

# Guochuan Tsai

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11817197/guochuan-tsai-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34  
papers

5,506  
citations

27  
h-index

36  
g-index

36  
ext. papers

5,869  
ext. citations

5.2  
avg, IF

5.32  
L-index

#	Paper	IF	Citations
34	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , <b>1990</b> , 28, 18-25	9.4	541
33	D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , <b>1998</b> , 44, 1081-9	7.9	539
32	Glutamatergic mechanisms in schizophrenia. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2002</b> , 42, 165-79	17.9	515
31	Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. <i>Archives of General Psychiatry</i> , <b>1995</b> , 52, 829-36		375
30	Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1003, 318-27	6.5	356
29	N-acetylaspartate in neuropsychiatric disorders. <i>Progress in Neurobiology</i> , <b>1995</b> , 46, 531-40	10.9	352
28	A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. <i>Archives of General Psychiatry</i> , <b>1999</b> , 56, 21-7		349
27	The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. <i>Annual Review of Medicine</i> , <b>1998</b> , 49, 173-84	17.4	325
26	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , <b>2004</b> , 55, 452-6	7.9	282
25	Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 522-37	3.3	210
24	Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 1207-13	11.9	201
23	Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 8485-90	11.5	173
22	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. <i>Psychopharmacology</i> , <b>2004</b> , 174, 32-8	4.7	172
21	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 645-9	7.9	148
20	NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. <i>International Review of Neurobiology</i> , <b>2004</b> , 59, 491-515	4.4	104
19	Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. <i>Brain Research</i> , <b>1991</b> , 556, 151-6	3.7	96
18	Ionotropic glutamate receptors as therapeutic targets in schizophrenia. <i>CNS and Neurological Disorders</i> , <b>2002</b> , 1, 183-9		91

17	A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. <i>Psychopharmacology</i> , <b>2005</b> , 179, 144-50	4.7	88
16	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). <i>Journal of Comparative Neurology</i> , <b>1992</b> , 315, 217-29	3.4	88
15	Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. <i>Biological Psychiatry</i> , <b>2002</b> , 51, 493-7	7.9	85
14	Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. <i>Journal of Neurochemistry</i> , <b>1988</b> , 51, 1956-9	6	64
13	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. <i>Biological Psychiatry</i> , <b>1998</b> , 44, 667-74	7.9	62
12	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. <i>Neuroscience Letters</i> , <b>1989</b> , 100, 295-300	3.3	45
11	NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5169-79	3.3	44
10	Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5180-5	3.3	40
9	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. <i>Journal of Physiology</i> , <b>2005</b> , 563, 777-93	3.9	38
8	Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. <i>Journal of Chemical Neuroanatomy</i> , <b>1993</b> , 6, 277-92	3.2	28
7	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. <i>Synapse</i> , <b>2009</b> , 63, 625-35	2.4	22
6	The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. <i>European Journal of Neuroscience</i> , <b>2009</b> , 30, 2308-17	3.5	17
5	Assessing and treating cognitive impairment in schizophrenia: current and future. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5127-38	3.3	15
4	NMDA pathology and treatment of schizophrenia. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5118-26	3.3	14
3	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. <i>Brain Research</i> , <b>1993</b> , 629, 305-9	3.7	13
2	Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission. <i>Recent Patents on CNS Drug Discovery</i> , <b>2009</b> , 4, 220-38		11
1	Promoter analysis of human glutamate carboxypeptidase II. <i>Brain Research</i> , <b>2007</b> , 1170, 1-12	3.7	3